Блокаторы ренин-ангиотензин-альдостероновой системы в лечении артериальной гипертензии: существующие доказательства и перспективы

1. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 3–25.
2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
3. Wong ND, Dede J, Chow VH et al. Global cardiovascular risk associated with hypertension and extent of treatment and control according to risk group. Am J Hypertens 2012; 25: 561–7.
4. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of rennin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33: 2088–97.
5. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB–MI paradox. Circulation 2006; 114: 838–54.
6. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342: d2234.
7. Savarese G, Costanzo P, Cleland JG et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013; 61: 131–42.
8. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of rennin-angiotensin system blockade. Am J Cardiol 2010; 105 (Suppl. 1): 10A–20A.
9. Athyros VG, Mikhailidis DP, Kakafika AI et al. Angiotensin II reactivation and aldosterone escape phenomena in rennin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529–35.
10. Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate EUROPA story. Drugs 2009; 69: 265–77.
11. Unger T, Stoppelhaar M. Rationale for double rennin-angiotensin-aldosterone system blockade. Am J Cardiol 2007; 100: 25J–31J.
12. Segall L, Covic A, Goldsmith DJ. Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol Dial Transplant 2007; 22: 2435–9.
13. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
14. Barnett AH, Bain SC, Bouter P et al. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952–61.
15. Yusuf S, Diener HC, Sacco RL et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225–37.
16. Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–83.
17. McDonald MA, Simpson SH, Ezekowitz JA et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005; 331: 873.
18. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381–6.
19. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005; 23: 2113–8.
20. Turnbull F, Neal B, Pfeffer M et al. Blood pressure-dependent and independent effects of agents that inhibit the rennin-angiotensin system. J Hypertens 2007; 25: 951–8.
21. Dahlo..f B, Devereux RB, Kjeldsen SE et al for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
22. Fuchs FD. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet 2002; 359: 2203.
23. Kato J, Eto T. Diuretics in the LIFE study. Lancet 2004; 364: 413.
24. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–9.
25. Disertori M, Latini R, Barlera S et al. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606–17.
26. Yusuf S, Healey JS, Pogue J et al. ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364: 928–38.
27. Goette A, Scho..n N, Kirchhof P et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Circ Arrhythm Electrophysiol 2012; 5: 43–51.
28. Yamashita T, Inoue H, Okumura K et al. Randomized trial of angiotensin II-receptor blocker versus dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace 2011; 13: 473–9.
29. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. McMurray JJ, Holman RR, Haffner SM et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477–90.
31. Haller H, Ito S, Izzo JL Jr et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.
32. Imai E, Chan JC, Ito S et al. ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54: 2978–86.
33. Rubio-Tapia A, Herman ML, Ludvigsson JF et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87: 732–8.
34. Mochizuki S, Dahlo..f B, Shimizu M et al. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.
35. Sawada T, Yamada H, Dahlo..f B, Matsubara H. KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: 
KYOTO HEART Study. Eur Heart J 2009; 30: 2461–9.
36. Yui Y. Concerns about the Jikei Heart Study. Lancet 2012; 379: e48.
37. Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; 30: 2461–9; Eur Heart J 2013; 34: 1023.
38. Retraction–Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2013; 382: 843.
39. Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
40. Dahlo..f B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
41. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40.
42. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl 
J Med 2008; 358: 1887–98.
43. Wing LM, Reid CM, Ryan P et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–92.
44. Yui Y, Sumiyoshi T, Kodama K et al. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–91.
45. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
46. Bulpitt CJ, Beckett NS, Cooke J et al. Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–17.
47. Ferrari R, Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Rev Cardiovasc Ther 2013; 11: 705–17.
48. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. 
N Engl J Med 2008; 359: 2417–28.
49. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2,5 mg: results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev 2011; 18: 107–13.
50. Карпов Ю.А. Программа ФОРТИССИМО: преимущества фиксированной полнодозовой комбинации периндоприла аргинина и индапамида в лечении плохо контролируемой артериальной гипертонии. Кардиология. 2013; 3: 37–43.
51. Farsang C. Picasso Investigators. Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Press 2013; 22 Suppl 1: 3–10.

С.Г.Канорский

Кафедра терапии №2 ФПК и ППС ГБОУ ВПО Кубанский государственный медицинский университет Минздрава России